MMED (NASDAQ:MMED) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of MMED (NASDAQ:MMED) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $22.10.

Several analysts have recently issued reports on the company. Bank of America initiated coverage on MMED in a report on Tuesday. They set a “buy” rating and a $27.00 target price on the stock. Piper Sandler began coverage on shares of MMED in a research report on Tuesday. They set a “neutral” rating and a $16.00 price objective for the company. Wells Fargo & Company began coverage on shares of MMED in a research note on Tuesday. They set an “overweight” rating and a $26.00 price objective on the stock. William Blair began coverage on shares of MMED in a research report on Tuesday. They issued an “outperform” rating for the company. Finally, Mizuho started coverage on shares of MMED in a report on Tuesday. They set an “outperform” rating and a $21.00 price target for the company.

MMED News Summary

Here are the key news stories impacting MMED this week:

• Positive Sentiment: Goldman Sachs initiated coverage with a “Buy” rating and a $24.00 price target (≈67% upside), signalling strong confidence from a large sell‑side firm.
• Positive Sentiment: Wells Fargo started coverage with an “Overweight” rating and a $26.00 target (≈81% upside), one of the highest targets among recent initiations.
• Positive Sentiment: Bank of America initiated with a “Buy” and a $27.00 target (≈88% upside), another aggressive bullish call. Article Title
• Positive Sentiment: BTIG began coverage with a “Buy” and a $25.00 target (≈74% upside), adding to the cluster of high targets. Article Title
• Positive Sentiment: Citigroup initiated coverage with a “Buy” and a $23.00 price target (≈60% upside).
• Positive Sentiment: Mizuho started coverage with an “Outperform” and a $21.00 target (≈46% upside).
• Positive Sentiment: Evercore initiated an “Outperform” with a $20.00 target (≈39% upside).
• Positive Sentiment: Morgan Stanley initiated with an “Overweight” and a $19.00 target (≈32% upside). Article Title
• Positive Sentiment: William Blair initiated coverage with an “Outperform” (price target not stated in the feed), adding boutique sell‑side support.
• Neutral Sentiment: Piper Sandler started coverage with a “Neutral” rating and a $16.00 target (≈11.5% upside), the most cautious of the new initiations.
• Neutral Sentiment: Separately, a Piper Sandler‑linked note was summarized as a “Hold” in a TipRanks piece that highlights execution risks relative to franchise strength — a more cautious take that could temper enthusiasm. Balancing Franchise Strength with Execution Risks: Why MiniMed Merits a Hold Rating

MMED Stock Performance

MMED stock traded up $0.84 during mid-day trading on Tuesday, reaching $15.19. 167,413 shares of the company were exchanged, compared to its average volume of 1,029,044. MMED has a 12 month low of $14.10 and a 12 month high of $20.48.

About MMED

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.